LimaCorporate
20 Apr_2021

LimaCorporate is proud to announce the first surgery performed in the Stemless Reverse Shoulder System Investigational Device Exemption (IDE) study.

LimaCorporate is proud to announce the first surgery performed in the Stemless Reverse Shoulder System Investigational Device Exemption (IDE) study.
The IDE, approved by FDA last November, allows LimaCorporate evaluate the safety and effectiveness of our Stemless Reverse Shoulder System compared to our Reverse Shoulder System in a randomized, multi-center comparative clinical trial.

This study is an exceptional opportunity for LimaCorporate as there are currently no stemless reverse implants cleared for use by the FDA. LimaCorporate’s IDE study on the Stemless Reverse System, which aims to enroll 200 patients at eight U.S. investigational sites with two-year follow-up, is a pivotal first step to address this unmet need in the U.S. shoulder arthroplasty market.
The IDE Study makes us even more confident about the future: new products, new projects, and activities are growing and taking shape.

Read the full press release here

Other news

28 Sep_2022

Proudly Together at the 59° SECOT national congress

23 Sep_2022

Focus Session for the Amigos del Hombro

12 Sep_2022

Massimo Calafiore appointed as new LimaCorporate Chief Executive Officer

16 Jun_2022

Time to meet and L.E.A.R.N. together!

01 Jun_2022

Together at the 9° JOINT AEA-SEROD Congress

27 May_2022

Are you ready to L.E.A.R.N.?